甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效剖析.docVIP

甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效剖析 　　[摘要] 目的 观察并探讨甲磺酸阿帕替尼治疗晚期非小细胞肺癌的临床疗效。方法 随机选取该院于2014年1月―2016年12月期间收治的68例晚期非小细胞肺癌患者当作研究对象，对患者的临床资料进行回顾性分析。根据治疗方案的不同，将68例晚期非小细胞肺癌患者分为实验组、对照组2组，各34例，实验组应用甲磺酸阿帕替尼进行治疗，对照组采取紫杉醇单药治疗方案。观察并对比分析2组的临床疗效及MMP-9、VEGF、CYFRA21-4以及CEA等指标的变化情况。结果 实验组的临床治疗总有效率为94.12%，明显高于对照组的73.53%，差异有统计学意义（P0.05）；治疗后，实验组的MMP-9[实验组（1 008.41±80.04）ng/mL，对照组（1 459.32±115.06）ng/mL]、VECF[实验组（285.33±35.20）ng/L，对照组（543.52±44.21）ng/L]、CYFRA21-4[实验组（4.48±0.45），对照组（5.84±0.65）]以及CEA[实验组（14.42±1.14），对照组（19.14±1.62）]明显优于对照组，差异有统计学意义（P0.05）。?Y论 甲磺酸阿帕替尼治疗晚期非小细胞肺癌，疗效确切，效果显著，值得推广。 　　[关键词] 甲磺酸阿帕替尼；晚期非小细胞肺癌；疗效 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）04（c）-0113-03 　　[Abstract] Objective To observe the clinical curative effect of methylsulfonic acid and apatinib in treatment of advanced non-small cell lung cancer. Methods 68 cases of patients with advanced non-small cell lung cancer admitted and treated in our hospital from January 2014 to December 2016 were selected and randomly divided into two groups according to the different treatment plans with 34 cases in each， the experimental group were treated with methylsulfonic acid and apatinib， while the control group adopted the paclitaxel single drug， and the clinical curative effect and changes of MMP-9、VEGF、CYFRA21-4 and CAE were compared between the two groups. Results The total clinical effective rate in the experimental group was obviously higher than that in the control group（94.12% vs 73.53%）， and the difference was statistically significant（P0.05）， after treatment， the MMP-9、VEGF、CYFRA21-4 and CAE in the experimental group were obviously better than those in the control group， [（1008.41±80.04）ng/mL， （285.33±35.20）ng/L， （4.48±0.45）， （14.42±1.14） vs （1 459.32±115.06）ng/mL， （543.52±44.21）ng/L， （5.84±0.65）， （19.14±1.62）]， and the differences were statistically significant（P 　　[Key words] Methylsulfonic acid and apatinib； Advanced non-small cell lung cancer； Curative effect 　　阿帕替尼是一种分子靶向抗肿瘤药物，可用于治疗胃癌、晚期非鳞非小细胞肺癌、肝癌[1]。该研究通过回顾性分析68例晚期非小